Brian S. Tyler Sells 8,961 Shares of McKesson Co. (NYSE:MCK) Stock

McKesson Co. (NYSE:MCK) CEO Brian S. Tyler sold 8,961 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the transaction, the chief executive officer now owns 69,625 shares of the company’s stock, valued at approximately $41,820,952.50. This represents a 11.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

McKesson Stock Up 0.8 %

MCK stock opened at $598.61 on Wednesday. The company’s fifty day simple moving average is $587.30 and its 200 day simple moving average is $562.13. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $637.51. The firm has a market cap of $75.99 billion, a price-to-earnings ratio of 27.41, a PEG ratio of 1.30 and a beta of 0.52.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Research analysts expect that McKesson Co. will post 32.69 earnings per share for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.47%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson’s dividend payout ratio (DPR) is 13.00%.

Institutional Trading of McKesson

Hedge funds have recently modified their holdings of the stock. Millstone Evans Group LLC bought a new stake in McKesson in the fourth quarter valued at $28,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of McKesson in the 3rd quarter valued at about $29,000. RPg Family Wealth Advisory LLC bought a new stake in McKesson in the 3rd quarter valued at about $31,000. Synergy Asset Management LLC acquired a new position in McKesson during the 4th quarter worth approximately $32,000. Finally, Crews Bank & Trust bought a new position in McKesson in the fourth quarter worth approximately $33,000. Institutional investors own 85.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MCK shares. Wells Fargo & Company increased their price target on McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research note on Friday, December 13th. Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Morgan Stanley lifted their price target on McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Robert W. Baird raised McKesson from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $531.00 to $688.00 in a research note on Thursday, November 7th. Finally, Bank of America cut their target price on shares of McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, McKesson has an average rating of “Moderate Buy” and a consensus target price of $645.79.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.